WAMU 88.5 : Metro Connection

Filed Under:

Georgetown Doc Works Toward Personalized Cancer Care

Play associated audio
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology
Jonathan Wilson
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology

About seven years ago, the laboratory run by Dr. Richard Schlegel at Georgetown University's Department of Pathology developed the technology for the first vaccine for Human Papillomavirus or HPV — a virus that can lead to cervical cancer. Now Dr. Schlegel's lab appears to have made another big discovery — one that could eventually change the way doctors treat all kinds of cancer. Metro Connection's Jonathan Wilson talked with doctor in his office at Georgetown University to find out what the lab's latest breakthrough medical trial revealed.

Dr. Schlegel explaining the concept of reprogrammed cells: "The finding that we have come upon, is that we have a way to grow normal and tumor cells from a patient very rapidly and very efficiently, which hasn't been able to be accomplished before. What it allows us to be able to do now is to go in and take a biopsy of someone's tumor, with a needle, for example, like a breast tumor if you had a biopsy, and within days have tumor cells growing out of there and normal cells if you have a normal area. So you can identify drugs that kill the tumor cells, and not the normal cells."

On how it could change cancer treatments: "You may have a drug that's known, to say, treat a lung tumor, in most cases, you'll get a response, but they [the tumors] come back. And then it becomes a game of oncology experimentation. I hate to say that, but you know, you don't know what's going to work, but you try another drug on the patient. And if it works, good, if it doesn't you move on to another one. The bad thing about that is every time you use a new drug on a patient, there's a lot of toxicity associated with it. So with each different round of chemotherapy, the patient gets sicker and sicker. So what we're able to do with this, we hope — when it gets tested in much larger trials — is to use the laboratory to define the spectrum of drugs that would be good to use on the patient and avoid all of the toxicities. We are not just going to take a drug off the shelf - drug 'x' is best for this population of patients who have lung tumors. We will actually take your tumor, and find out what drug is best for you. That's the ultimate goal."

Dr. Schlegel and his researchers caution that it could be years before validation studies on their work is completed, and government approval is granted for broader use of the new technique.


[Music: "House MD Theme" by Massive Attack from House MD Original Television Soundtrack]

NPR

Peruvians Love Their Chicha Street Art. The Government ... Not So Much

Walk down a street in Peru and you'll likely see an example of the glow-in-the-dark posters and murals. Lots of people love them. But the upper crust — and the government — aren't impressed.
NPR

Tea-Infused Sweets: Chocolate + Jasmine Tea Is A Match Made In Heaven

Smoky and floral brews can provide a kick of flavor to desserts, especially when blended with chocolate. Pastry chef Naomi Gallego shows us a few tricks for surprising the palate with tea.
WAMU 88.5

America's First Ladies

They walk a tricky line: closest adviser to the President of the United States and hostess in chief. A new book examines the evolution of the role of first lady of the United States.

WAMU 88.5

E-Cigarettes and Vaping

Last week, the D.C. Council voted to designate e-cigarettes and "similar vapor products containing nicotine" as tobacco products. That means that their sales tax will jump from the regular 5.75% sales tax to the 70% tax that's tacked onto sales of products like cigarettes and cigars. We explore what this means for the evolving public health debate surrounding e-cigarettes.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.